$APLS News

Last published 6mo ago

6mo agoAPLS BIIBBiogen Completes Acquisition of Apellis PharmaceuticalsGlobeNewswireCAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the successful completion of the acquisition of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS). Apellis, a leader in advancing
7mo agoAPLS BIIBBiogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into NephrologyGlobeNewswireAcquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in
8mo agoAPLSApellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of DirectorsGlobeNewswireWALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently,
8mo agoAPLSApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireFull-year 2025 net product revenues of $689 million SYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® (pegcetacoplan) full year 2025 net product revenue of $102
8mo agoAPLSApellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care
8mo agoAPLSApellis Announces Eight Oral Presentations at the 49th Macula Society Annual MeetingGlobeNewswireCompany will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis
9mo agoAPLSApellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025
10mo agoAPLSApellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireFull-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe planned in 1H
10mo agoAPLSApellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12,
11mo agoAPLSThe New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGNGlobeNewswireRobust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent results across
11mo agoAPLSApellis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Citi's
12mo agoAPLSApellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 YearsGlobeNewswireWALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with
1y agoAPLSApellis Pharmaceuticals to Present at the Stifel 2025 Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at
1y agoAPLSApellis Pharmaceuticals Reports Third Quarter 2025 Financial ResultsGlobeNewswireGenerated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product salesReceived 152 new patient start forms for EMPAVELI® (pegcetacoplan) in the first two months since launch in C3G and primary
1y agoAPLSNew One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney WeekGlobeNewswireSignificant proteinuria reduction maintained at one year, regardless of immunosuppressant use or baseline proteinuria levels Complete proteinuria remission (UPCR ≤0.5 g/g) achieved in one-third of patients and sustained
1y agoAPLSApellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial ResultsGlobeNewswireApellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 F, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will
1y agoAPLSApellis Pharmaceuticals, Inc. (APLS) Presents At Baird Global Healthcare Conference (Transcript)Earnings Call Transcripts
1y agoAPLSApellis Pharmaceuticals, Inc. (APLS) Presents At Cantor Global Healthcare Conference 2025 (Transcript)Earnings Call Transcripts
1y agoAPLSApellis Pharmaceuticals, Inc. (APLS) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 TranscriptEarnings Call Transcripts
1y agoAPLSApellis Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that management will participate in webcast fireside chats at the following investor conferences: Wells
1y agoAPLSApellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoAPLSApellis Pharmaceuticals Reports Second Quarter 2025 Financial ResultsGlobeNewswireReceived U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPGNAnnounced capped royalty purchase agreement with Sobi under which Apellis receives up
1y agoAPLSFDA Approves Apellis' EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and OlderGlobeNewswireProven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 deposits Broad label includes adults and adolescents with C3G or
1y agoAPLSApellis Pharmaceuticals to Host Conference Call on July 31, 2025, to Discuss Second Quarter 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., July 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2025 financial
1y agoAPLSApellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific MeetingGlobeNewswireWALTHAM, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that five abstracts were accepted for oral presentation at the American Society of Retina Specialists (ASRS)
1y agoAPLSApellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)GlobeNewswireApellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGNNon-dilutive financing further strengthens Apellis' balance sheet Apellis retains full U.S.
1y agoAPLSApellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGNGlobeNewswireRobust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the European Renal
1y agoAPLSApellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswireWALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday,
1y agoAPLSApellis Pharmaceuticals Reports First Quarter 2025 Financial ResultsGlobeNewswireGenerated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of
1y agoAPLSApellis Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will participate in the following May investor conferences: BofA Securities 2025 Healthcare
1y agoAPLSApellis Pharmaceuticals to Host Conference Call on May 7, 2025, to Discuss First Quarter 2025 Financial ResultsGlobeNewswireWALTHAM, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its first quarter 2025 financial
1y agoAPLSApellis Announces Craig Wheeler to Join the Board of DirectorsGlobeNewswireWALTHAM, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the
1y agoAPLSApellis Announces FDA Acceptance and Priority Review of the Supplemental New Drug Application for EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGNGlobeNewswirePDUFA target action date is July 28, 2025 WALTHAM, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the U.S. Food and Drug Administration (FDA) has accepted
1y agoAPLS BIIB BMYCardurion Pharmaceuticals Appoints Karen Lewis as Chief People OfficerBusiness WireCardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis
1y agoAPLSApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireReported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product revenue of $611.9 millionEMPAVELI® (pegcetacoplan) full
1y agoAPLSApellis Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care ConferenceGlobeNewswireWALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025,
1y agoAPLSApellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGNGlobeNewswireWALTHAM, Mass. and STOCKHOLM, Sweden, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and Sobi® (STO:SOBI) today announced the European Medicines Agency (EMA) has validated an
1y agoAPLSApellis Pharmaceuticals to Host Conference Call on February 28, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireWALTHAM, Mass., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2024
1y agoAPLSApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that the company approved the grant of equity awards to three new employees with a grant date of February 3,
1y agoAPLSApellis Receives Approval of SYFOVRE® (pegcetacoplan) in Australia for Geographic Atrophy (GA)GlobeNewswireWALTHAM, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that the Therapeutic Goods Administration (TGA) has approved SYFOVRE® (pegcetacoplan) for the
1y agoAPLSApellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireReports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net product
1y agoAPLSApellis Announces Keli Walbert to Join the Board of DirectorsGlobeNewswireWALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms. Walbert brings more
1y agoAPLSApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity
1y agoAPLSApellis Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13,
1y agoAPLSApellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireWALTHAM Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity
1y agoAPLSApellis Pharmaceuticals to Present at Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) today announced that the company will participate in the following December investor conferences: Evercore ISI HealthCONx
1y agoAPLSApellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday,
2y agoAPLSApellis Pharmaceuticals, Inc. (APLS) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAPLSApellis Pharmaceuticals Reports Third Quarter 2024 Financial ResultsGlobeNewswireGenerated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by 7% quarter-over-quarter, with U.S. net product revenue of $152.0
2y agoAUPH APLS CMPI TPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...